AR030188A1 - Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos - Google Patents
Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanosInfo
- Publication number
- AR030188A1 AR030188A1 ARP010100463A ARP010100463A AR030188A1 AR 030188 A1 AR030188 A1 AR 030188A1 AR P010100463 A ARP010100463 A AR P010100463A AR P010100463 A ARP010100463 A AR P010100463A AR 030188 A1 AR030188 A1 AR 030188A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrocarbyl
- substituted
- heterocycle
- groups
- subject
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229940123237 Taxane Drugs 0.000 abstract 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 2
- -1 alkenoxy Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos de taxano sustituidos con ésteres en el C7, que tienen la formula: (1) donde Ac es acetilo; Bz es benzoilo; R7 es RaCOO-; R10 es hidroxilo; X3 es alquilo, alquenilo, alquinilo o heterociclo sustituido o insustituido; X5 es ûCOX10, -COOX10 o ûCONHX10; X10 es hidrocarbilo, hidrocarbilo sustituido o heterociclo; y Ra es hidrocarbilo, hidrocarbilo sustituido o heterociclo, donde dicho hidrocarbilo o hidrocarbilo sustituido contiene átomos de carbono en las posiciones alfa y beta respecto del carbono en el cual Ra es un sustituyente. Preferiblemente, los grupos hidrocarbilo o hidrocarbilo sustituido incluyen grupos alquilo, alquenilo, alquinilo y arilo que comprenden de 1 a 20 átomos de carbono. Los sustituyentes pueden incluir halogeno heterociclo, alcoxi, alquenoxi, alquinoxi, ariloxi, hidroxilo, hidroxilo protegido, aciloxi, nitro amino, ciano, tiol, cetales, acetales, y éteres. Preferiblemente, los grupos arilo denotan grupos aromáticos homocíclicos opcionalmente sustituidos, más preferiblemente grupos monocíclicos o bicíclicos que contienen de 6 a 12 átomos de carbono en la porcion del anillo. Preferiblemente el grupo heteroarilo denota grupos aromáticos o no aromáticos monocíclicos o bicíclicos, opcionalmente saturados, completamente saturados o sin saturar, que tienen al menos un heteroátomo en al menos un heteroátomo en el al menos un anillo seleccionado entre átomos de oxígeno, azufre y nitrogeno; y preferiblemente 5 o 6 átomos en cada anillo. Los ejemplos de heterociclos incluyen furilo, tienilo, piridilo, oxazolilo, pirrolilo, indolilo, quinolinilo o isoquinilinilo y semejantes. Los presentes compuestos de taxano tienen excepcional utilidad como agentes antitumor. Composiciones farmacéuticas que comprenden los taxanos y uno o más diluyentes o coadyuvantes inertes o fisiologicamente activos aceptables para el uso farmacéutico. Proceso para tratar un sujeto mamífero que sufre de una condicion que responde a los taxanos que comprende la administracion oral, topica o parenteral al sujeto de la composicion farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17979400P | 2000-02-02 | 2000-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030188A1 true AR030188A1 (es) | 2003-08-13 |
Family
ID=22658029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100463A AR030188A1 (es) | 2000-02-02 | 2001-01-31 | Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US6610860B2 (es) |
| EP (1) | EP1183253B8 (es) |
| JP (1) | JP2003522167A (es) |
| KR (1) | KR100784161B1 (es) |
| CN (1) | CN1362955A (es) |
| AR (1) | AR030188A1 (es) |
| AT (1) | ATE396188T1 (es) |
| AU (1) | AU776051B2 (es) |
| BG (1) | BG65279B1 (es) |
| BR (1) | BR0104749A (es) |
| CA (1) | CA2368993C (es) |
| CO (1) | CO5280224A1 (es) |
| CZ (1) | CZ298484B6 (es) |
| DE (1) | DE60134094D1 (es) |
| DK (1) | DK1183253T3 (es) |
| ES (1) | ES2307588T3 (es) |
| GE (1) | GEP20043322B (es) |
| HK (1) | HK1047938A1 (es) |
| HU (1) | HUP0200917A3 (es) |
| IL (1) | IL145641A0 (es) |
| MX (1) | MXPA01009901A (es) |
| MY (1) | MY137637A (es) |
| NO (1) | NO327982B1 (es) |
| NZ (1) | NZ514409A (es) |
| PL (1) | PL202668B1 (es) |
| PT (1) | PT1183253E (es) |
| RO (1) | RO121777B1 (es) |
| RU (1) | RU2265017C2 (es) |
| SA (1) | SA01220045B1 (es) |
| SK (1) | SK13712001A3 (es) |
| TR (1) | TR200102856T1 (es) |
| TW (1) | TWI291873B (es) |
| UA (1) | UA75573C2 (es) |
| WO (1) | WO2001057027A1 (es) |
| ZA (1) | ZA200108060B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5280224A1 (es) | 2000-02-02 | 2003-05-30 | Univ Florida State Res Found | Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen |
| US6638973B2 (en) * | 2000-02-02 | 2003-10-28 | Fsu Research Foundation, Inc. | Taxane formulations |
| CA2354486A1 (en) * | 2001-07-31 | 2003-01-31 | Florida State University Research Foundation, Inc. | C7 ester substituted taxanes |
| SG125889A1 (en) * | 2001-08-01 | 2006-10-30 | Univ Florida State Res Found | C7 ester subsituted taxanes |
| KR100819578B1 (ko) * | 2001-08-01 | 2008-04-04 | 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 | Ｃ７ 에스테르 치환된 탁산 |
| US20030082229A1 (en) * | 2001-11-01 | 2003-05-01 | Board Of Regents, The University Of Texas Systems | Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use |
| US8012950B2 (en) * | 2003-08-29 | 2011-09-06 | Wisconsin Alumni Research Foundation | Method to diagnose and treat degenerative joint disease |
| US7745650B2 (en) | 2003-09-25 | 2010-06-29 | Tapestry Pharmaceuticals, Inc | 9,10-α,α-OH-taxane analogs and methods for production thereof |
| EP1810968A3 (en) * | 2003-09-25 | 2007-08-08 | Tapestry Pharmaceuticals, Inc. | 9, 10-a, a-OH-taxane analogs and methods for production thereof |
| US7160919B2 (en) | 2004-03-05 | 2007-01-09 | Florida State University Research Foundation, Inc. | C7 lactyloxy-substituted taxanes |
| TW200533339A (en) | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| CN101438252A (zh) * | 2004-10-07 | 2009-05-20 | 爱莫里大学 | 多功能纳米粒子共轭体及其应用 |
| EP1805192B1 (en) | 2004-10-25 | 2012-10-17 | Dekk-Tec, Inc. | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents |
| US20060216767A1 (en) * | 2005-03-22 | 2006-09-28 | Saladax Biomedical Inc. | Docetaxel immunoassay |
| PL217731B1 (pl) | 2006-06-01 | 2014-08-29 | Tomasz Byrski | Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi |
| EP1913958B1 (en) * | 2006-08-03 | 2009-12-23 | Sanofi-Aventis | Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab |
| US11786504B2 (en) | 2006-09-28 | 2023-10-17 | Tapestry Pharmaceuticals, Inc. | Taxane analogs for the treatment of brain cancer |
| US11873308B2 (en) | 2006-11-06 | 2024-01-16 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
| WO2008121476A1 (en) | 2007-03-28 | 2008-10-09 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
| WO2008098138A1 (en) | 2007-02-07 | 2008-08-14 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthetic macrocyclic compounds for treating cancer |
| WO2008109360A1 (en) | 2007-02-28 | 2008-09-12 | Tapestry Pharmaceuticals, Inc | Taxane analogs for the treatment of brain cancer |
| AU2008236684B2 (en) | 2007-04-06 | 2013-04-18 | Ziopharm Oncology, Inc. | Salts of isophosphoramide mustard and analogs thereof |
| MX2011001122A (es) | 2008-07-31 | 2011-03-29 | Ziopharm Oncology Inc | Sintesis y formulaciones de sales de mostaza de isofosforoamida y analogos de las mismas. |
| CA2753041A1 (en) | 2009-02-24 | 2010-09-02 | Dekk-Tec, Inc. | Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents |
| WO2010138686A1 (en) | 2009-05-29 | 2010-12-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mdri-inverse agents |
| WO2011112867A1 (en) | 2010-03-10 | 2011-09-15 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas |
| WO2012033601A1 (en) | 2010-08-20 | 2012-03-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Thiosemicarbazones with mdr1 - inverse activity |
| CN103781495A (zh) | 2011-07-11 | 2014-05-07 | 美国政府(由卫生和人类服务部的部长所代表) | 光敏抗体-荧光团缀合物 |
| US20150157580A1 (en) | 2012-05-25 | 2015-06-11 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of regulating cannabinoid receptor activity-related disorders and diseases |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
| CN106470705B (zh) | 2014-08-08 | 2020-03-31 | 美国政府(由卫生和人类服务部的部长所代表) | 在体内和在体外的靶标的光控移除 |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| WO2019099615A1 (en) | 2017-11-17 | 2019-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth |
| EP3774912A1 (en) | 2018-04-10 | 2021-02-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation |
| KR20220031054A (ko) | 2019-07-02 | 2022-03-11 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Egfrviii에 결합하는 단일클론 항체 및 이의 용도 |
| WO2021154705A1 (en) | 2020-01-27 | 2021-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rab13 and net1 antisense oligonucleotides to treat metastatic cancer |
| PE20231175A1 (es) | 2020-11-19 | 2023-08-01 | Kalivir Immunotherapeutics Inc | Inmunoterapia oncolitica por remodelacion del microambiente tumoral |
| EP4284439A1 (en) | 2021-01-29 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer |
| IL308018B2 (en) | 2021-04-30 | 2025-04-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for altered MHC expression |
| WO2024006965A1 (en) | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
| WO2025014896A1 (en) | 2023-07-07 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| SE463189B (sv) | 1989-03-13 | 1990-10-22 | Eston Joensson | Preparat avsett att tillfoeras amalgamfyllningar i taender foer att daerigenom hindra eller minska avgaang av kvicksilver eller kvicksilveraanga |
| US5175315A (en) | 1989-05-31 | 1992-12-29 | Florida State University | Method for preparation of taxol using β-lactam |
| FR2679230B1 (fr) | 1991-07-16 | 1993-11-19 | Rhone Poulenc Rorer Sa | Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent. |
| US5714513A (en) | 1991-09-23 | 1998-02-03 | Florida State University | C10 taxane derivatives and pharmaceutical compositions |
| US5227400A (en) | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
| US5243045A (en) | 1991-09-23 | 1993-09-07 | Florida State University | Certain alkoxy substituted taxanes and pharmaceutical compositions containing them |
| US5721268A (en) | 1991-09-23 | 1998-02-24 | Florida State University | C7 taxane derivatives and pharmaceutical compositions containing them |
| SG46582A1 (en) | 1991-09-23 | 1998-02-20 | Univ Florida State | 10-Desacetoxytaxol derivatives |
| US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
| US5489601A (en) * | 1991-09-23 | 1996-02-06 | Florida State University | Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them |
| US5430160A (en) | 1991-09-23 | 1995-07-04 | Florida State University | Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides |
| RU2059631C1 (ru) * | 1991-11-29 | 1996-05-10 | Дзе Юниверсити оф Канзас | Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью |
| EP1001036B1 (en) | 1992-01-15 | 2004-10-20 | E.R. Squibb & Sons, Inc. | Enzymatic processes for resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes |
| US5272171A (en) | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
| US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
| US5352806A (en) | 1992-04-17 | 1994-10-04 | Abbott Laboratories | Taxol derivatives |
| US5248796A (en) | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
| US5319112A (en) | 1992-08-18 | 1994-06-07 | Virgnia Tech Intellectual Properties, Inc. | Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol |
| WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
| CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
| CA2119261C (en) | 1992-12-23 | 2006-01-31 | Michael A. Poss | Novel sidechain-bearing taxanes and intermediates thereof |
| IL108443A0 (en) * | 1993-01-29 | 1994-04-12 | Univ Florida State | C7 taxane derivatives and pharmaceutical compositions containing them |
| US5703247A (en) | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
| DE69425563T2 (de) * | 1993-03-22 | 2001-01-25 | Florida State University, Tallahassee | Taxane mit amino-substituierter seitenkette |
| DE69434374T2 (de) * | 1993-03-22 | 2005-11-24 | Florida State University, Tallahassee | Taxane mit Furyl oder Thienyl enthaltender substituierter Seitenkette |
| ATE209489T1 (de) * | 1993-03-22 | 2001-12-15 | Univ Florida State | Taxane mit pyridyl-substituierter seitenkette |
| EP0982302B1 (en) | 1993-06-11 | 2004-04-14 | PHARMACIA & UPJOHN COMPANY | Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them |
| IL109926A (en) | 1993-06-15 | 2000-02-29 | Bristol Myers Squibb Co | Methods for the preparation of taxanes and microorganisms and enzymes utilized therein |
| TW397866B (en) | 1993-07-14 | 2000-07-11 | Bristol Myers Squibb Co | Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes |
| FR2711369B1 (fr) | 1993-10-20 | 1995-11-17 | Rhone Poulenc Rorer Sa | Nouveaux taxoïdes, leur préparation et les compositions qui les contiennent. |
| US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| US5414869A (en) * | 1993-11-26 | 1995-05-16 | Thomson; Margaret I. | Knotless scarf and method of making same |
| FR2721024B1 (fr) * | 1994-06-09 | 1996-07-12 | Rhone Poulenc Rorer Sa | Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
| JPH10508022A (ja) * | 1994-10-28 | 1998-08-04 | ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク | タキソイド誘導体、それらの製造、およびそれらの抗腫瘍薬としての使用 |
| TW354293B (en) | 1995-06-06 | 1999-03-11 | Bristol Myers Squibb Co | Prodrugs of paclitaxel derivatives |
| US5780653A (en) | 1995-06-07 | 1998-07-14 | Vivorx Pharmaceuticals, Inc. | Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers |
| CA2231837A1 (en) | 1995-09-13 | 1997-03-20 | Florida State University | Radiosensitizing taxanes and their pharmaceutical preparations |
| US5767297A (en) | 1997-02-05 | 1998-06-16 | Ensuiko Sugar Refining Co., Ltd. | Taxoid derivative and method of producing thereof |
| FR2745814B1 (fr) * | 1996-03-06 | 1998-04-03 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| WO1997042181A1 (en) | 1996-05-06 | 1997-11-13 | Florida State University | 1-deoxy baccatin iii, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof |
| WO1997044027A1 (en) * | 1996-05-17 | 1997-11-27 | Merck & Co., Inc. | Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases |
| ATE196844T1 (de) * | 1996-05-22 | 2000-10-15 | Protarga Inc | Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| US5811452A (en) | 1997-01-08 | 1998-09-22 | The Research Foundation Of State University Of New York | Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof |
| US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
| US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
| DE69729128T2 (de) * | 1997-10-08 | 2005-04-28 | Bio Research Corporation Of Yokohama, Yokohama | Taxoid-derivate und verfahren zu ihrer herstellung |
| US6136988A (en) | 1998-04-10 | 2000-10-24 | Hauser, Inc. | 7-hexanoyltaxol and methods for preparing the same |
| US5964739A (en) * | 1998-06-18 | 1999-10-12 | Champ; Raynido A. | Safety disposable needle structure |
| US6146659A (en) | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| EP1192126A1 (en) | 1999-06-21 | 2002-04-03 | Napro Biotherapeutics, Inc. | C-2 hydroxyl protected-n-acyl(2r,3s)-3-phenylisoserine activated esters and methods for production thereof |
| US6348215B1 (en) * | 1999-10-06 | 2002-02-19 | The Research Foundation Of State University Of New York | Stabilization of taxane-containing dispersed systems |
| CO5280224A1 (es) | 2000-02-02 | 2003-05-30 | Univ Florida State Res Found | Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen |
| US6638973B2 (en) * | 2000-02-02 | 2003-10-28 | Fsu Research Foundation, Inc. | Taxane formulations |
| NZ514073A (en) | 2000-02-02 | 2004-02-27 | Univ Florida State Res Found | Taxane formulations having improved solubility |
| IT1319168B1 (it) | 2000-03-17 | 2003-09-26 | Indena Spa | Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono. |
-
2001
- 2001-01-31 CO CO01007075A patent/CO5280224A1/es not_active Application Discontinuation
- 2001-01-31 AR ARP010100463A patent/AR030188A1/es not_active Application Discontinuation
- 2001-02-02 BR BR0104749-3A patent/BR0104749A/pt not_active IP Right Cessation
- 2001-02-02 TR TR2001/02856T patent/TR200102856T1/xx unknown
- 2001-02-02 HK HK03100173.6A patent/HK1047938A1/zh unknown
- 2001-02-02 WO PCT/US2001/003385 patent/WO2001057027A1/en not_active Ceased
- 2001-02-02 KR KR1020017012600A patent/KR100784161B1/ko not_active Expired - Fee Related
- 2001-02-02 PL PL350026A patent/PL202668B1/pl not_active IP Right Cessation
- 2001-02-02 HU HU0200917A patent/HUP0200917A3/hu unknown
- 2001-02-02 CA CA002368993A patent/CA2368993C/en not_active Expired - Fee Related
- 2001-02-02 JP JP2001557859A patent/JP2003522167A/ja active Pending
- 2001-02-02 US US09/775,851 patent/US6610860B2/en not_active Expired - Fee Related
- 2001-02-02 IL IL14564101A patent/IL145641A0/xx unknown
- 2001-02-02 DK DK01905349T patent/DK1183253T3/da active
- 2001-02-02 AT AT01905349T patent/ATE396188T1/de not_active IP Right Cessation
- 2001-02-02 MX MXPA01009901A patent/MXPA01009901A/es active IP Right Grant
- 2001-02-02 DE DE60134094T patent/DE60134094D1/de not_active Expired - Fee Related
- 2001-02-02 UA UA2001106734A patent/UA75573C2/uk unknown
- 2001-02-02 GE GE4514A patent/GEP20043322B/en unknown
- 2001-02-02 MY MYPI20010481A patent/MY137637A/en unknown
- 2001-02-02 AU AU33239/01A patent/AU776051B2/en not_active Ceased
- 2001-02-02 NZ NZ514409A patent/NZ514409A/xx unknown
- 2001-02-02 PT PT01905349T patent/PT1183253E/pt unknown
- 2001-02-02 EP EP01905349A patent/EP1183253B8/en not_active Expired - Lifetime
- 2001-02-02 SK SK1371-2001A patent/SK13712001A3/sk unknown
- 2001-02-02 CN CN01800306A patent/CN1362955A/zh active Pending
- 2001-02-02 RU RU2001129507/04A patent/RU2265017C2/ru not_active IP Right Cessation
- 2001-02-02 CZ CZ20013503A patent/CZ298484B6/cs not_active IP Right Cessation
- 2001-02-02 RO ROA200101085A patent/RO121777B1/ro unknown
- 2001-02-02 ES ES01905349T patent/ES2307588T3/es not_active Expired - Lifetime
- 2001-03-06 TW TW090102237A patent/TWI291873B/zh active
- 2001-04-11 SA SA1220045A patent/SA01220045B1/ar unknown
- 2001-10-01 ZA ZA200108060A patent/ZA200108060B/en unknown
- 2001-10-01 BG BG105967A patent/BG65279B1/bg unknown
- 2001-10-01 NO NO20014759A patent/NO327982B1/no not_active IP Right Cessation
-
2003
- 2003-06-25 US US10/606,027 patent/US7186849B2/en not_active Expired - Fee Related
-
2007
- 2007-01-09 US US11/621,321 patent/US20070249708A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030188A1 (es) | Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos | |
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| BRPI0517461A (pt) | compostos farmacêuticos | |
| MX9205309A (es) | Nuevos taxanos substituidos con furilo y tienilo y composiciones farmaceuticas que los contienen | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| ES2039278T3 (es) | Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides. | |
| SV2002000097A (es) | Inhibidores de metaloproteasas ref.pcs10322/82940 /bb | |
| AR068503A1 (es) | Derivados de amidas sustituidas, composicion farmaceutica y usos. | |
| GT200000002A (es) | Ureas difenilicias x - carboxyaril sustituidas como inhibidores raf kinase. | |
| AR039985A1 (es) | Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| AR051698A1 (es) | Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| ES2051772T3 (es) | 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos. | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR035580A1 (es) | Compuestos inhibidores de ifata, compuestos intermediarios, procedimientos de preparacion y su uso en la preparacion de medicamentos | |
| KR910006241A (ko) | 피리미딘-4,6-디카복실산 디아미드, 이의 제조방법, 이의 용도 및 이들 화합물을 기초로 하는 약제 | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| CO2025015814A2 (es) | Inhibidores de kras de 2-azabiciclo [2.2.1] heptano | |
| AR007021A1 (es) | Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos | |
| CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
| PE20220169A1 (es) | Compuestos macrociclicos como agonistas de sting | |
| AR006340A1 (es) | Derivados de 2-(3h)-oxazolona, proceso para prepararlos, composiciones farmaceuticas que los incluyan y uso de dichos derivados para tratamientosmedicinales. | |
| MX9205792A (es) | Derivados novedosos de asa-androstan 178-substituidos | |
| AR016198A1 (es) | Un compuesto que es un derivado de distamicina sustituido con acriloilo, su uso, un procedimiento para prepararlo y una composicion farmaceutica que locomprende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |